Presentation on theme: "Therapeutic applications of anti- CD20 monoclonal antibodies - tumors and beyond Jakub Golab Department of Immunology Medical University of Warsaw CHMP/PDCO/CMDh."— Presentation transcript:
Therapeutic applications of anti- CD20 monoclonal antibodies - tumors and beyond Jakub Golab Department of Immunology Medical University of Warsaw CHMP/PDCO/CMDh Presidency meeting
Emil Adolf von Behring Marburg University Nobel prize in 1901 "for his work on serum therapy…
Georges Köhler Basel Institute for Immunology César Milstein MRC Laboratory of Molecular Biology Cambridge Nobel prize in 1984 "for the discovery of the principle for production of monoclonal antibodies"
Types of monoclonal antibodies murine antibodychimeric antibody (66% of human sequence) humanised antibody (90% of human sequence) human antibody (100% of human sequence) murine Fab murine FV Fab Fc
Development of novel anti-CD20 monoclonal antibodies:
Rituximab-mediated complement dependent cytotoxicity against control and statin-treated lymphoma cells Winiarska et al. PLoS Med. 2008;5(3):e64.
and why this finding might be important … ? Because 30-40 million people all over the world are long- term statin users The estimated number of people that should be using statins at the time being is 200 million
Number of cells Fluorescence intensity Winiarska et al. PLoS Med. 2008;5(3):e64.
PE – intracellular tail of CD20 FITC – extracellular loop of CD20 Winiarska et al. PLoS Med. 2008;5(3):e64.
Cancer is a disease of elderly people Increasing age is associated with: complex changes in physiology (alterations in renal and hepatic functions, decreased bone marrow reserve) Increased number of comorbid diseases (cardiovascular diseases, diabetes, rheumatic diseases, neuropsychiatric disorders) Elderly people usually take multiple different drugs: antidiabetics statins diuretics β-blockers antidepressants anti-inflammatory drugs Cancer patients are unlikely to give up these treatments!!!
Potential future uses of anti-CD20 monoclonal antibodies rheumatoid arthritis multiple sclerosis systemic lupus erythematosus autoimmune anemia autoimmune hemolytic anemia pure red cell aplasia idiopathic thrombocytopenic purpura (ITP) Wegener's granulomatosis bullous skin disorders (pemphigus, pemphigoid) type 1 diabetes mellitus Sjogren's syndrome thyroid-associated ophthalmopathy A new study from Norway suggests that rituximab (together with methotrexate) might help patients with chronic fatigue syndrome. A clinical trial is ongoing.
Some figures were prepared using Servier Medical Art (www.servier.com) Acknowledgements Magdalena Winiarska, Jacek Bil, Dominika Nowis, Małgorzata Wańczyk, Marcin Makowski, Tomasz Świtaj, Kamil Bojarczuk, Eliza Głodkowska, Piotr Mrówka, Paweł Salwa, Tadeusz Issat, Zuzanna Kurzaj, Witold Lasek, Tomasz Stokłosa, Marek Jakóbisiak Department of Immunology Medical University of Warsaw Cezary WójcikDepartment of Anatomy and Cell Biology, IUSM, USA Grzegorz M. WilczyńskiNencki Institute of Experimental Biology Wendy J.M. Mackus Patrick J. Engelberts Paul W.H.I. Parren Genmab, Utrecht, The Netherlands Łukasz BojarskiInternational Institute of Molecular and Cell Biology, Warsaw Maciej Siński, Ewa Wilczek, Grzegorz Basak, Zbigniew Gaciong, Elżbieta Górska, Maria Wąsik Medical University of Warsaw Anna Dąbrowska-IwanickaMaria Sklodowska-Curie Memorial Cancer Center Krzysztof WarzochaInstitute of Hematology, Warsaw Kazimierz SułekDepartment of Clinical Hematology, Military Medical Institute
T E A M Improvement of antitumor effectiveness of photodynamic therapy In coooperation with: Patrizia Agostinis (Catholic University of Leuven, Belgium) Michael Hamblin (Wellmans Center of Photomedicine, Boston, USA) Jacek Capala (National Institutes of Health, Bethesda, USA) TEAM members: Dr. Małgorzata Firczuk Dr. Magdalena Winiarska MSc. Małgorzata Jodłowska MSc. Angelika Szokalska BSc. Justyna Chlebowska BSc. Paweł Salwa BSc. Kamil Bojarczuk BSc. Magdalena Gabrysiak TEAM coordinator: prof. Jakub Golab TEAM consultant: Dr. Dominika Nowis